Covid is ongoing8 Oct 2020 10:50
Vlad has confirmed nothing is on hold and sounds bullish.From previous Covid related RNS:https://www.lse.co.uk/rns/HEMO/covid-19-project-initiated-9nyfqjoi1z57oxn.html"Using its humanized mice, the Advanced peripheral blood Hematopoietic Chimera ("ApbHC"), which were developed to model blood and autoimmune diseases and to test treatments, Hemogenyx will seek to discover human neutralizing antibodies - antibodies that are typically developed by the human immune system to neutralize invading viral pathogens - that could be used to fight SARS-CoV-2 (the virus that causes COVID-19) infections.""Concurrently, Hemogenyx has initiated a pilot study to understand why some individuals who are infected with SARS-CoV-2 are asymptomatic, some exhibit mild symptoms and some become very sick. Such understanding could prove essential for both the development of new treatments for COVID-19 and managing the current risk of infection. Should the study prove to be successful, Hemogenyx will aim to develop and commercialize a test that could identify people with potentially high/low risk of severe illness caused by the virus."https://www.lse.co.uk/rns/HEMO/result-of-agm-and-completion-of-placing-5o1velh8pld1s9s.html"The fundraising will also enable the Company to progress its own work on COVID-19 and other viruses considerably more intensively. The Company had already been developing treatments to be deployed against other viral pathogens prior to the onset of COVID-19. The Company's ApbHC mice have been developed in part as a discovery platform for the development of such treatments. The Directors believe, for example, that the ApbHC could potentially be used as a tool for the rapid discovery and/or isolation of human antibodies against previously unknown viruses such as the novel coronavirus or other natural or engineered human-specific pathogens, referred to in biodefence circles as "Disease X"."https://www.lse.co.uk/rns/HEMO/covid-19-project-update-epv9mgx9omt302i.html"The additional funds raised recently have enabled the Company to take these and other developments forward significantly and at a faster pace.""Meanwhile, as announced on 22 April 2020, the Company has progressed its work, currently using blood samples from convalescent patients, to attempt to establish why some individuals who are infected with SARS-CoV-2 are asymptomatic, some exhibit mild symptoms, and some become very sick. This work will be of value in developing new forms of treatment, and especially in managing infection risk and assisting individuals better to establish their real risk of getting sick."
Sign In
Follow the stocks
